Hence, CAR T cells targeting EGFR variant 3 (EGFRvIII), which is only expressed on malignant tumor cells (mostly glioblastomas), showed significant efficacy in treating mouse models of glioblastomas (73) and exhibited in vivo safety based on the current result of a phase I study at the University of Pennsylvania (NCT02209376) (61, 74). This evidence concerns the gene EGFR and glioblastoma.